The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC)

Thrombosis and Haemostasis

Volumn 101, Issue 4, 2009, Pages 691-695

  Van Vliet, Huib A A M ^a   Tchaikovski, Svetlana N ^b   Rosendaal, Frits R ^a   Rosing, Jan ^b   Helmerhorst, Frans M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Activated protein C resistance; Hemostasis; Intrauterine device; Venous thrombosis

Indexed keywords

ACTIVATED PROTEIN C; COPPER INTRAUTERINE DEVICE; LEVONORGESTREL;

ADOLESCENT; ADULT; ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HORMONAL CONTRACEPTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; ORAL CONTRACEPTION; PREGNANCY; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ADULT; BIOLOGICAL MARKERS; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRAUTERINE DEVICES, COPPER; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MIDDLE AGED; PEDIGREE; RISK ASSESSMENT; RISK FACTORS; THROMBIN; TIME FACTORS; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 64849114049     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-09-0621     Document Type: Article

References (22)

1. Vandenbroucke J P, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527-1535.
2. Rosendaal FR, Van Hylckama Vlieg A, Tanis BC, et al. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003; 1: 1371-1380.
3. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Br Med J 2001; 323: 131-134.
4. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358: 1427-1429.
5. Mirena website. Available at: http://www.mirenaus.com. Accessed August 7, 2008.
6. Shulman L P, Nelson AL, Darney PD. Recent developments in hormone delivery systems. Am J Obstet Gynecol 2004; 190: S39-S48.
7. Jensen JT. Contraceptive and therapeutic effects of the levonorgestrel intrauterine system: an overview. Obstet Gynecol Surv 2005; 60: 604-612.
8. Electronic Medicines Compendium. Available at: http://emc.medicines.org. uk. Accessed August 7, 2008.
9. Vasilakis C, Jick H, Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999; 354: 1610-1611.
10. Heinemann LA, Assmann A, DoMinh T, et al. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 1999; 4: 67-73.
11. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998; 57: 315-324.
12. WHO. Medical eligibility criteria for contraceptive use. Available at: http://www.who.int/reproductivehealth/publications/mec/summary.html. Accessed at August 7, 2008.
13. Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036-2040.
14. van Vliet HA, Winkel TA, Noort I, et al. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost 2004; 2: 2060-2062.
15. Alhenc-Gelas M, Plu-Bureau, Guillonneau S, et al. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. J Thromb Haemost 2004; 2: 1594-1600.
16. Tans G, van Hylckama Vlieg A, Thomassen MC, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003; 122: 465-470.
17. Tchaikovski S, van Vliet HAAM, Thomassen CLGD, et al. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography (CAT). Thromb Haemost 2007; 98: 1350-1356
18. Nicolaes GA, Thomassen MC, van Oerle R, et al. A prothrombinase-based assay for detection of resistance to activated protein C. Thromb Haemost 1996; 76: 404-410.
19. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-1276.
20. Kemmeren JM, Algra A, Meijers JC, et al. Effect of second- and third generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized controlled trial. Blood 2004; 103: 927-33.
21. Lindqvist PG, Rosing J, Malmquist A, et al. Etonogestrel implant use is not related to hypercoagulable changes in anticoagulant system. J Thromb Haemost 2003; 1: 601-602.
22. Curvers J, Thomassen MC, Rimmer J, et al. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost 2002; 88: 5-11.